Skip to main content

Advertisement

Figure 1 | SpringerPlus

Figure 1

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

Figure 1

Progression-free survival (PFS) and overall survival (OS) by treatment arm. (A) PFS: platinum combination, median PFS = 4.2 months; docetaxel monotherapy, median PFS = 2.3 months. (B) OS: platinum combination, median OS = 16.5 months; docetaxel monotherapy, median OS = 13.0 months.

Back to article page